



JUN 13 2002

TECH CENTER 1600/2900  
P10158.00A (08-09)

JUN 11 2002

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
to a collection of information unless it displays a valid OMB control number.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to this collection of information unless it displays a currently valid OMB control number.

Substitute for form 1449A/PTO

(use as many sheets as necessary)

Sheet 1 of 4

<i>Application Number</i>	10/017,180
<i>Filing Date</i>	December 7, 2001
<i>First Named Inventor</i>	Wiegand
<i>Group Art Unit</i>	1614
<i>Examiner Name</i>	
<i>Attorney Docket Number</i>	JBP-571

## U.S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

[illegible]

Examiner Signature		Date Considered	6/17/12
-----------------------	---	--------------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RECEIVED

JUN 13 2002



PTO/SB/08A (08-00)

Approved for use through 10/31/2002, P. 51, 2002

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

10/01/2000/2900

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 4

Application Number	10/017,180
Filing Date	December 7, 2001
First Named Inventor	Wiegand
Group Art Unit	1614
Examiner Name	
Attorney Docket Number	JBP-571

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
K6		WILLIAM J. CUNLIFFE, Acne, 1989, 1-11, Martin Dunitz Ltd., UK.	
		S. COHEN, T. KAMARCK, R. MERMELSTEIN, A Global Measure of Perceived Stress, Journal of Health and Social Behavior 1983, 385-396, Vol 24 (December).	
		P. BRANTLEY, C. WAGGONER, G. JONES, N. RAPPAPORT, A Daily Stress Inventory: Development, Reliability, and Validity, Journal of Behavioral Medicine, 1987:61-75, Vol. 10, No.1.	
		T.R. COOPER, H.R. TRUNKFIELD, A.J. ZANELLA, W.D. BOOTH, An enzyme-linked Immunosorbent Assay for Cortisol in the Saliva of Man and Domestic Farm Animals, Journal of Endocrinology (1989) R13-R16.	
		A. BECK, G. BROWN, N. EPSTEIN, R. STEER, An Inventory for Measuring Clinical Anxiety: Psychometric Properties, Journal of Consulting and Clinical Psychology, 1988, 893-897, Vol. 56, No. 6.	
		A. BUSKE-KIRSCHBAUM, S. JOBST, A. WUSTMANS, C. KIRSCHBAUM, W. RAUH, D. HELLHAMMER, Attenuated Free Cortisol Response to Psychosocial Stress in Children with Atopic Dermatitis, Psychosomatic Medicine, 1997:419-426, Vol. 59.	
		A. SLOMINSKI, J. WORTSMAN, T. LUGER, R. PAUS, S. SOLOMON, Corticotropin Releasing Hormone and Proopiomelanocortin Involvement in the Cutaneous Response to Stress, Physiological Reviews, July 2000:979-1020, Vol. 80, No.3.	
		M. MOROHASHI, M. TOYADA, Y. LUO, S. HIGAKI, Cutaneous Neurologic Factors are Involved in the Pathogenesis of Acne, The Journal of Investigative Dermatology:820, 2000, Vol. 114 (Abstract)	
		E. AARDAL, A. CHARLOTTE HOLM, Cortisol in Saliva-Reference Ranges and Relation to Cortisol in Serum, European Journal Clin Chem, Clin Biochem 1995: 927-932, 33(No 12).	
		D. WATSON, L. CLARK, A. TELLEGEN, Development and Validation of Brief Measures of Positive and Negative Affect: The PANAS Scales, Journal of Personality and Social Psychology, 1988:1063-1070, Vol.54, No. 6.	
		O. WOLKOWITZ, V. REUS, A. KEEBLER, N. NELSON, M. FRIEDLAND, L. BRIZENDINE, E. ROBERTS, Double-Blind Treatment of Major Depression with Dehydroepiandrosterone, Am. J. Psychiatry, April 1999: 646-649, 156:4.	
		F. DHABHAR, B. MCEWEN, Enhancing versus suppressive effects of stress hormones on skin immune function, Proc. Natl. Acad. Sci. USA. 6(February 1999):1059-1064, Vol. 96.	
		P. SCHULZ, W. SCHLOTZ, Trierer Inventar zur Erfassung von chronischem Stress (TICS), Diagnostica 45, Heft 1, Hogrefe Verlag Gottingen 1999: 8-19	
		M. HOROWITZ, N. WILNER, W. ALVAREZ, Impact of Event Scale: A Measure of Subjective Stress, Psychosomatic Medicine, (May 1979):209-218, Vol 41, No. 3.	
K6		P. HUNT, E. GURNELL, F. HUPPERT, C. RICHARDS, A. PREVOST, J. WASS, J. HERBERT, V. CHATTERJEE, Improvement in Mood and Fatigue after Dehydroepiandrosterone Replacement in Addison's Disease in a Randomized, Double Blind Trial, The Journal of Clinical Endocrinology & Metabolism, 2000:4650-4656, Vol 85, No. 12.	

Examiner Signature	<i>Kushner</i>	Date Considered	6-15-03
--------------------	----------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



RECEIVED

JUN 13 2002

TECH CENTER 1600/2800

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 3 of 4

Application Number	10/017,180
Filing Date	December 7, 2001
First Named Inventor	Wiegand
Group Art Unit	1614
Examiner Name	
Attorney Docket Number	JBP-571

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
KG		M. CHREN, R. LASEK, S. FLOCKE, S. ZYZANSKI, Improved Discriminative and Evaluative Capability of a Refined Version of Skindex, a Quality-of-Life Instrument for Patients with Skin Diseases, Arch Dermatology, Nov. 1997:1433-1440, Vol 133.	
		J. KABAT-ZINN, E. WHEELER, T. LIGHT, A. SKILLINGS, M. SCHARF, T. CROPLEY, D. HOSMER, J. BERNHARD, Influence of a Mindfulness Meditation-Based Stress Reduction Intervention on Rates of Skin Clearing in Patients with Moderate to Severe Psoriasis Undergoing Phototherapy (UVB) and Photochemotherapy(PUVA), Psychosomatic Medicine (1998):625-632, Vol. 60.	
		J. KIECOLT-GLASER, R. GLASER, E. STRAIN, J. STOUT, K. TARR, J. HOLLIDAY, C. SPEICHER, Modulation of Cellular Immunity in Medical Students, Journal of Behavioral Medicine, (1986):5-21., Vol.9, No. 1.	
		N. BOLGER, E. SCHILLING, Personality and the Problems of Everyday Life: The Role of Neuroticism in Exposure and Reactivity to Daily Stressors, Journal of Personality, September 1991: 355-386, 59:3.	
		M. SULZBERGER, S. ZAIENS, Psychogenic Factors in Dermatologic Disorders, 1948:669-685.	
		A. GARG, M. CHREN, L. SANDS, M. MATSUI, K. MARENUS, K. FEINGOLD, P. ELIAS, Psychological Stress Perturbs Epidermal Permeability Barrier Homeostasis, Implications for the Pathogenesis of Stress-Associated Skin Disorders, Arch Dermatol, (Jan 2001)53-59., Vol. 137.	
		E. PANCONSESI, G. HAUTMANN, Psychophysiology of Stress in Dermatology: The Psychobiologic Pattern of Psychosomatics, Dermatologic Clinics, (July 1996):399-421., Vol. 14, Number 3.	
		C. KIRSCHBAUM, D. HELLHAMMER, Salivary Cortisol in Psychobiological Research: An Overview, Neuropsychobiology 1989:150-169, Vol. 22.	
		C. KIRSCHBAUM, D. HELLHAMMER, Salivary Cortisol in Psychoneuroendocrine Research: Recent Developments and Applications, Psychoneuroendocrinology, 1994, 313-333, Vol 19, No. 4.	
		M. DENDA, T. TSUCHIYA, P. ELIAS, K. FEINGOLD, Stress alters cutaneous permeability barrier homeostasis, Am. J. Physiol. Regulatory Integrative Comp. Physiol., 2000:R367-R372., Vo. 278.	
		R. A. DRESSENDORFER, C. KIRSCHBAUM, W. ROHDE, F. STAHL, C.J. STRASBURGER, Synthesis of a Cortisol-Biotin Conjugate and Evaluation as a Tracer in an Immunoassay for Salivary Cortisol Measurement, J. Steroid Biochem, Molec. Biol. 1992, 683-692, Vol 43, no. 7.	
KG		A. DELONGIS, S. FOLKMAN, R. LAZARUS, The Impact of Daily Stress on Health and Mood: Psychological and Social Resources as Mediators, Journal of Personality and Social Psychology, 1988:486-495, Vol 54, No. 3.	

Examiner Signature	<i>Kathleen M. G.</i>	Date Considered	6-19-03
-----------------------	-----------------------	--------------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington,

JUN 13 2002

O I P E JC100  
 JUN 11 2002  
 DATE

**TECH CENTER 1600/2900**

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

(use as many sheets as necessary)

Sheet 4 of 4

<i>Application Number</i>	10/017,180
<i>Filing Date</i>	December 7, 2001
<i>First Named Inventor</i>	Wiegand
<i>Group Art Unit</i>	1614
<i>Examiner Name</i>	
<i>Attorney Docket Number</i>	JBP-571

## OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

[illegible]

Examiner Signature		Date Considered	6.17.03
-----------------------	---	--------------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington,